Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance

S. Vincent Rajkumar, Robert A. Kyle, Terry M. Therneau, Raynell J. Clark, Arthur R. Bradwell, L. Joseph Melton, Dirk R. Larson, Matthew F. Plevak, Jerry A. Katzmann

Research output: Contribution to journalArticle

60 Scopus citations

Abstract

We hypothesized that the presence of monoclonal free light chains (FLC) in the serum of patients with monoclonal gammopathy of undetermined significance (MGUS) is a marker of clonal evolution and a risk factor for progression. Forty-seven patients with MGUS and documented progression to myeloma or related malignancy were compared with 50 age- and gender-matched patients with MGUS and no evidence of progression after 5 or more years of follow-up. The presence of an abnormal kappa/lambda FLC ratio in the serum was associated with a higher risk of MGUS progression (relative risk 2.5; 95% confidence interval: 1.6-4.0; P < 0.001).

Original languageEnglish (US)
Pages (from-to)308-310
Number of pages3
JournalBritish journal of haematology
Volume127
Issue number3
DOIs
StatePublished - Nov 2004

Keywords

  • Kappa light chains
  • Kappa/lambda free light chain ratio
  • Lambda light chains
  • Monoclonal gammopathy of undetermined significance
  • Progression

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance'. Together they form a unique fingerprint.

  • Cite this